Syeda Kanza Kazmi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Syeda Kanza Kazmi has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Wardah Hassan
Dow University of Health Sciences, Karachi, Pakistan
2 shared publications Aqsa Kabir
Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan
1 shared publication- Do Justin P. Canakis
Internal Medicine Resident Physician, George Washington University Medical Center, Washington, District of Columbia. ORCID: https://orcid.org/
1 shared publication - Fariha Hasan
Department of Internal Medicine, Cooper University Hospital, Camden, NJ, USA
1 shared publication - Firzan Nainu
Department of Pharmacy, Faculty of Pharmacy, Hasanuddin University, Makassar 90245, Indonesia
1 shared publication - Hanaa Tariq
Sindh Medical College, Jinnah Sindh Medical University, Karachi, Pakistan
1 shared publication
Latest Publications
- Open Access
- 30 October 2026
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 57 (1) , 249
Survival Outcomes in Metastatic Colorectal Cancer Patients with BRAF Mutations Undergoing Targeted Chemotherapy: A Reconstructed Individual Patient Data Meta-Analysis of Randomized Controlled Trials
Background: BRAF V600E–mutant metastatic colorectal cancer (mCRC) represents an aggressive molecular subtype associated with poor prognosis and limited response to conventional chemotherapy. Although multiple targeted strategies, including anti-vascular endothelial growth factor ( VEGF ), anti-epidermal growth factor receptor ( EGFR ), and BRAF -directed therapies, are used in clinical practice, their comparative effectiveness remains uncertain. We performed a reconstructed individual patient–data (IPD) meta-analysis of randomized controlled trials (RCTs) to evaluate survival outcomes across targeted therapeutic classes in BRAF -mutant mCRC. Methods: A systematic search of PubMed, Embase, Scopus, and Cochrane databases was conducted through July 2025 to identify RCTs reporting survival outcomes for BRAF -mutant mCRC. Kaplan–Meier curves were digitized and IPD reconstructed using established methods. A one-stage meta-analysis using Cox proportional hazards models was performed to estimate pooled overall survival (OS) and progression-free survival (PFS). Models were adjusted for study-level covariates and clustering, with Bonferroni correction applied for multiple comparisons. Results: Eighteen RCTs comprising 11,931 participants were included. Pooled median OS was 22.3 months for BRAF -directed regimens, 17.1 months for VEGF -targeted therapy, and 10.1 months for EGFR-directed therapy across studies evaluating first-line therapy. Across first-line studies, BRAF inhibitor directed regimen was associated with significantly improved OS compared with EGFR inhibition (HR 0.43, 95% CI 0.31–0.60; P < 0.001) and improved PFS (HR 0.47, 95% CI 0.42–0.53; P < 0.001). VEGF inhibition also demonstrated superior OS compared with EGFR inhibition (HR 0.56, 95% CI 0.38–0.81; p < 0.001). EGFR -directed regimen consistently demonstrated the poorest survival outcomes across analyses. Discussion: In this reconstructed IPD meta-analysis, BRAF -directed therapies were associated with the most favourable survival outcomes, whereas EGFR directed regimen demonstrated limited clinical benefit in BRAF -mutant mCRC. These results highlight the importance of biologically aligned pathway-targeted therapy and provide comparative evidence to inform treatment selection in this aggressive molecular subtype.
- 30 October 2026
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 57 (1) , 249
Open AccessSurvival Outcomes in Metastatic Colorectal Cancer Patients with BRAF Mutations Undergoing Targeted Chemotherapy: A Reconstructed Individual Patient Data Meta-Analysis of Randomized Controlled Trials
Background: BRAF V600E–mutant metastatic colorectal cancer (mCRC) represents an aggressive molecular subtype associated with poor prognosis and limited response to conventional chemotherapy. Although multiple targeted strategies, including anti-vascular endothelial growth factor ( VEGF ), anti-epidermal growth factor receptor ( EGFR ), and BRAF -directed therapies, are used in clinical practice, their comparative effectiveness remains uncertain. We performed a reconstructed individual patient–data (IPD) meta-analysis of randomized controlled trials (RCTs) to evaluate survival outcomes across targeted therapeutic classes in BRAF -mutant mCRC. Methods: A systematic search of PubMed, Embase, Scopus, and Cochrane databases was conducted through July 2025 to identify RCTs reporting survival outcomes for BRAF -mutant mCRC. Kaplan–Meier curves were digitized and IPD reconstructed using established methods. A one-stage meta-analysis using Cox proportional hazards models was performed to estimate pooled overall survival (OS) and progression-free survival (PFS). Models were adjusted for study-level covariates and clustering, with Bonferroni correction applied for multiple comparisons. Results: Eighteen RCTs comprising 11,931 participants were included. Pooled median OS was 22.3 months for BRAF -directed regimens, 17.1 months for VEGF -targeted therapy, and 10.1 months for EGFR-directed therapy across studies evaluating first-line therapy. Across first-line studies, BRAF inhibitor directed regimen was associated with significantly improved OS compared with EGFR inhibition (HR 0.43, 95% CI 0.31–0.60; P < 0.001) and improved PFS (HR 0.47, 95% CI 0.42–0.53; P < 0.001). VEGF inhibition also demonstrated superior OS compared with EGFR inhibition (HR 0.56, 95% CI 0.38–0.81; p < 0.001). EGFR -directed regimen consistently demonstrated the poorest survival outcomes across analyses. Discussion: In this reconstructed IPD meta-analysis, BRAF -directed therapies were associated with the most favourable survival outcomes, whereas EGFR directed regimen demonstrated limited clinical benefit in BRAF -mutant mCRC. These results highlight the importance of biologically aligned pathway-targeted therapy and provide comparative evidence to inform treatment selection in this aggressive molecular subtype.
- Open Access
- 1 January 2026
- Published by Wiley in Gastroenterology Research and Practice
- Vol. 2026 (1)
The Mediterranean Diet and Inflammatory Bowel Disease: A Comprehensive Systematic Review and Meta‐Analysis
Introduction: Diet significantly influences the progression of inflammatory bowel disease (IBD). The Mediterranean diet (MD), characterized by high consumption of fruits, vegetables, healthy fats, lean proteins, and limited intake of processed foods, is recommended as adjunctive therapy. This meta‐analysis is aimed at evaluating existing data on dietary management in ulcerative colitis (UC) and assessing the effectiveness of MD in achieving symptomatic remission or improvement in IBD patients compared with other dietary interventions. Methods: Following Cochrane and PRISMA guidelines, we compared MD with alternative dietary interventions in IBD patients. Randomized controlled trials (RCTs) were identified through comprehensive database searches up to November 2024. Data were analyzed using RevMan Web, employing a random‐effects model. Results: Four RCTs involving a total of 339 IBD patients were included in this analysis. Among these, 167 patients (UC and CD) received the MD, whereas 172 followed non‐Mediterranean diets (NMD). The MD was associated with a statistically significant improvement in clinical remission compared with NMD (RR 1.18, p = 0.02). In subgroup analyses, clinical remission was not statistically different in UC (RR 1.15, 95% CI: 0.94–1.41, p = 0.78) or CD (RR 1.22, 95% CI: 1.00–1.47, p = 0.05). When compared specifically with a regular diet, MD significantly reduced both CRP levels (MD −2.66, p < 0.00001) and fecal calprotectin (MD −229.46, p = 0.008). Specifically, within the UC population, MD significantly decreased CRP and fecal calprotectin levels. Discussion: Our findings indicate that the MD significantly benefits IBD management, especially UC, as demonstrated by notable reductions in inflammatory markers. Benefits in CD remain unclear despite prior evidence. Future research should clarify benefits across patient subgroups and address adherence challenges.
- 1 January 2026
- Published by Wiley in Gastroenterology Research and Practice
- Vol. 2026 (1)
Open AccessThe Mediterranean Diet and Inflammatory Bowel Disease: A Comprehensive Systematic Review and Meta‐Analysis
Introduction: Diet significantly influences the progression of inflammatory bowel disease (IBD). The Mediterranean diet (MD), characterized by high consumption of fruits, vegetables, healthy fats, lean proteins, and limited intake of processed foods, is recommended as adjunctive therapy. This meta‐analysis is aimed at evaluating existing data on dietary management in ulcerative colitis (UC) and assessing the effectiveness of MD in achieving symptomatic remission or improvement in IBD patients compared with other dietary interventions. Methods: Following Cochrane and PRISMA guidelines, we compared MD with alternative dietary interventions in IBD patients. Randomized controlled trials (RCTs) were identified through comprehensive database searches up to November 2024. Data were analyzed using RevMan Web, employing a random‐effects model. Results: Four RCTs involving a total of 339 IBD patients were included in this analysis. Among these, 167 patients (UC and CD) received the MD, whereas 172 followed non‐Mediterranean diets (NMD). The MD was associated with a statistically significant improvement in clinical remission compared with NMD (RR 1.18, p = 0.02). In subgroup analyses, clinical remission was not statistically different in UC (RR 1.15, 95% CI: 0.94–1.41, p = 0.78) or CD (RR 1.22, 95% CI: 1.00–1.47, p = 0.05). When compared specifically with a regular diet, MD significantly reduced both CRP levels (MD −2.66, p < 0.00001) and fecal calprotectin (MD −229.46, p = 0.008). Specifically, within the UC population, MD significantly decreased CRP and fecal calprotectin levels. Discussion: Our findings indicate that the MD significantly benefits IBD management, especially UC, as demonstrated by notable reductions in inflammatory markers. Benefits in CD remain unclear despite prior evidence. Future research should clarify benefits across patient subgroups and address adherence challenges.
- Open Access
- 1 January 2022
- Published by Elsevier in Indian Heart Journal
- Vol. 74 (1) , 13-21
Short- and long-term cardiovascular outcomes in insulin-treated versus non-insulin-treated diabetes mellitus patients after percutaneous coronary intervention: A systematic review and meta-analysis
- 1 January 2022
- Published by Elsevier in Indian Heart Journal
- Vol. 74 (1) , 13-21
Open AccessShort- and long-term cardiovascular outcomes in insulin-treated versus non-insulin-treated diabetes mellitus patients after percutaneous coronary intervention: A systematic review and meta-analysis
- Open Access
- 1 December 2021
- Published by Narra Sains Indonesia in Narra J
- Vol. 1 (3)
Global acceptance and hesitancy of COVID-19 vaccination: A narrative review
The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a major global health threat to human civilization and has disrupted many aspects of the community around the globe. Vaccination is one of the prominent measures to control the COVID-19 pandemic. More than 120 vaccines have entered human clinical trials and at least 8 vaccines have been fully approved. However, the success of the COVID-19 vaccination programs depends on how the community accepts the vaccines. Despite COVID-19 vaccination having been initiated for a while now, more than 50% of the global population have not been vaccinated. In some low- and middle-income countries (LMICs), the vaccine coverage is less than 20%. Since the decision to accept the new vaccine is complex, understanding the factors underpinning vaccine acceptance is critical. This review aimed to summarize the COVID-19 vaccine acceptance rate around the globe as well as its associated determinants. Information from this study might be important to formulate effective strategies to increase the COVID-19 vaccine coverage, and to be able to achieve herd immunity.
- 1 December 2021
- Published by Narra Sains Indonesia in Narra J
- Vol. 1 (3)
Open AccessGlobal acceptance and hesitancy of COVID-19 vaccination: A narrative review
The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a major global health threat to human civilization and has disrupted many aspects of the community around the globe. Vaccination is one of the prominent measures to control the COVID-19 pandemic. More than 120 vaccines have entered human clinical trials and at least 8 vaccines have been fully approved. However, the success of the COVID-19 vaccination programs depends on how the community accepts the vaccines. Despite COVID-19 vaccination having been initiated for a while now, more than 50% of the global population have not been vaccinated. In some low- and middle-income countries (LMICs), the vaccine coverage is less than 20%. Since the decision to accept the new vaccine is complex, understanding the factors underpinning vaccine acceptance is critical. This review aimed to summarize the COVID-19 vaccine acceptance rate around the globe as well as its associated determinants. Information from this study might be important to formulate effective strategies to increase the COVID-19 vaccine coverage, and to be able to achieve herd immunity.